Larimar Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Larimar Therapeutics, Inc. (LRMR) on October 27, 2020. The filing discloses the entry into a material definitive agreement regarding the sublease of the Company's primary office space.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a specific lease agreement.
Material Changes and Agreements
On October 27, 2020, the Company entered into a Sublease agreement with Massachusetts Municipal Association, Inc. Key terms include:
- Property: Approximately 17,705 square feet at 3 Center Plaza, Boston, Massachusetts.
- Background: The Company originally acquired this non-cancellable operating lease from Shigo Center Plaza Owner, LLC in May 2020 following the merger of Chondrial Therapeutics, Inc. and Zafgen, Inc.
- Sublease Term: Commences upon landlord consent and continues until October 30, 2029.
- Rent Structure: Initial annual base rent is $849,840, increasing annually to a maximum of $991,480.
- Abatement: Rent abatement is provided until April 1, 2021, following the first monthly payment.
- Additional Costs: The Subtenant is responsible for future increases in operating costs (starting January 1, 2022), annual tax costs (starting July 1, 2021), and all utility costs (starting March 1, 2021).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary contingency noted is that the Sublease term officially commences only after the Company receives consent from the original landlord.
Investor Verification Points
- Verify the status of landlord consent required to activate the Sublease term.
- Confirm the impact of the rent abatement period on the Company's cash flow for the remainder of 2020 and early 2021.
- Review the full text of the Sublease (Exhibit 10.1) for any additional covenants or termination rights not summarized in this report.